Body composition changes in 308 Norwegian HIV-positive patients

被引:10
作者
Bergersen, BM [1 ]
Sandvik, L
Bruun, JN
机构
[1] Ullevaal Univ Hosp, Dept Infect Dis, NO-0407 Oslo, Norway
[2] Ullevaal Univ Hosp, Clin Res Ctr, NO-0407 Oslo, Norway
关键词
D O I
10.1080/00365540410019273
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This is the first study where HIV-associated body composition changes are described in a Scandinavian cohort. All HIV-positive patients living in Oslo who attended our outpatient clinic (n=407) were invited to participate. 308 patients (78%) were included. Lipodystrophy (LD) prevalence was 37.3% in patients on antiretroviral therapy (ART+)compared to 10.9% in patients without ART (p<0.001). Prominent veins and combined fat atrophy/accumulation were exclusively found in the ART+ group. Determinants of prominent veins were skin fold thickness, duration of nucleoside reverse transcriptase inhibitor treatment, duration of protease inhibitor treatment and current use of stavudine. When patients with and without LD were compared, breast circumference was 10.6 cm larger in LD+ women than in LD+ women (p=0.003). Chest pain was reported in 26.5% of LD+ compared to 3.9% (p<0.001) of LD- patients. This may be associated with an increased level of creatin kinase in LD+ compared to LD- patients (161+/-179 U/l vs 102+/-68, p=0.004). Eight years after HIV diagnosis 59.1% of the patients with LD had a regular job and 59.4% reported no or small problems with ART.
引用
收藏
页码:186 / 191
页数:6
相关论文
共 20 条
[1]   Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs - The Swiss HIV cohort study [J].
Bernasconi, E ;
Boubaker, K ;
Junghans, C ;
Flepp, M ;
Furrer, HJ ;
Haensel, A ;
Hirschel, B ;
Boggian, K ;
Chave, JP ;
Opravil, M ;
Weber, R ;
Rickenbach, M ;
Telenti, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (01) :50-55
[2]   Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[3]  
Calista D, 2000, EUR J DERMATOL, V10, P292
[4]   An objective case definition of lipodystrophy in HIV-infected adults: a case-control study [J].
Carr, A ;
Emery, S ;
Law, I ;
Puls, R ;
Lundgren, JD ;
Powderly, WG ;
Carr, B ;
Cooper, DA ;
Grinspoon, S ;
Ioannidis, J ;
Lewis, R ;
Law, M ;
Lichtenstein, K ;
Murray, J ;
Pizzuti, D ;
Rozenbaum, W ;
Schambelan, M ;
Moore, A ;
Miller, J .
LANCET, 2003, 361 (9359) :726-735
[5]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[6]   Lipodystrophy associated with an HIV-protease inhibitor [J].
Carr, A ;
Cooper, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18) :1296-1296
[7]   HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study [J].
Carr, A ;
Hudson, J ;
Chuah, J ;
Mallal, S ;
Law, M ;
Hoy, J ;
Doong, N ;
French, M ;
Smith, D ;
Cooper, DA .
AIDS, 2001, 15 (14) :1811-1822
[8]  
Colson AE, 2002, J ACQ IMMUN DEF SYND, V30, P27, DOI 10.1097/00042560-200205010-00004
[9]  
COOPER DA, 1999, ANTIVIR THER, V4, P75
[10]   MITOCHONDRIAL MYOPATHY CAUSED BY LONG-TERM ZIDOVUDINE THERAPY [J].
DALAKAS, MC ;
ILLA, I ;
PEZESHKPOUR, GH ;
LAUKAITIS, JP ;
COHEN, B ;
GRIFFIN, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (16) :1098-1105